Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-19-042264
Filing Date
2019-11-08
Accepted
2019-11-08 16:16:33
Documents
63
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q clsd-10q_20190930.htm 10-Q 1503206
2 EX-10.1 clsd-ex101_29.htm EX-10.1 58230
3 EX-31.1 clsd-ex311_6.htm EX-31.1 16724
4 EX-31.2 clsd-ex312_8.htm EX-31.2 16700
5 EX-32.1 clsd-ex321_9.htm EX-32.1 9027
  Complete submission text file 0001564590-19-042264.txt   5539322

Data Files

Seq Description Document Type Size
6 XBRL INSTANCE DOCUMENT clsd-20190930.xml EX-101.INS 1059500
7 XBRL TAXONOMY EXTENSION SCHEMA clsd-20190930.xsd EX-101.SCH 47959
8 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE clsd-20190930_cal.xml EX-101.CAL 46354
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE clsd-20190930_def.xml EX-101.DEF 172955
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE clsd-20190930_lab.xml EX-101.LAB 385463
11 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE clsd-20190930_pre.xml EX-101.PRE 296213
Mailing Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA 2Q 30005
Business Address 900 NORTH POINT PARKWAY SUITE 200 ALPHARETTA 2Q 30005 678-270-3631
Clearside Biomedical, Inc. (Filer) CIK: 0001539029 (see all company filings)

IRS No.: 452437375 | State of Incorp.: GA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37783 | Film No.: 191204258
SIC: 2834 Pharmaceutical Preparations